A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

Similar Items

• The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
  by: P. Jobanputra, et al.
  Published: (2002-01-01)
• Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
  by: K Malottki, et al.
  Published: (2011-03-01)
• Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
  by: Martínez-Pérez Rosalía, et al.
  Published: (2011-11-01)
• Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis Hepatotoxicidad recurrente asociada a etanercept y adalimumab pero no a infliximab en una paciente con artritis reumatoide
  by: José Carlos Titos-Arcos, et al.
  Published: (2012-05-01)
• Avaliação econômica das anticitocinas adalimumabe, etanercepte e infliximabe no tratamento da artrite reumatoide no Estado do Paraná Economic evaluation of anticitokines adalimumab, etanercept and infliximab for treatment of rheumatoid arthritis in Paraná State, Brazil
  by: Rafael Venson, et al.
  Published: (2011-01-01)